Overview and Scope
Cystic fibrosis (CF) therapeutics refers to medications that thin and facilitate coughing up lung mucus. It is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body.
Sizing and Forecast
The cystic fibrosis (cf) therapeutics market size has grown rapidly in recent years. It will grow from $6.91 billion in 2023 to $7.63 billion in 2024 at a compound annual growth rate (CAGR) of 10.4%. The growth in the historic period can be attributed to advancements in targeted therapies, growing understanding of cf genetics, patient advocacy and awareness, government support for research, orphan drug designations, incentives for rare disease research..
The cystic fibrosis (cf) therapeutics market size is expected to see strong growth in the next few years. It will grow to $10.59 billion in 2028 at a compound annual growth rate (CAGR) of 8.6%. The growth in the forecast period can be attributed to rise in cf patient population, regulatory approvals for novel therapies, focus on personalized medicine, increasing investment in biomarker research, expanded newborn screening programs, healthcare policy support.. Major trends in the forecast period include expansion of cftr modulators, gene editing technologies, early intervention strategies, improved diagnostic techniques, telehealth and remote monitoring, healthcare digitalization, chronic disease management..
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/cystic-fibrosis-cf-therapeutics-global-market-report
Segmentation & Regional Insights
The cystic fibrosis (cf) therapeutics market covered in this report is segmented –
1) By Drug Class: Pancreatic Enzyme Supplements, Mucolytic, Bronchodilators, CFTR Modulators
2) By Route Of Administration: Oral, Inhaled
3) By Treatment Method: Medication, Devices
North America was the largest region in the cystic fibrosis (CF) therapeutics market in 2023. Asia-Pacific is expected to be the fastest-growing region in the cystic fibrosis (CF) therapeutics market during the forecast period. The regions covered in the cystic fibrosis (cf) therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample_request?id=9056&type=smp
Major Driver Impacting Market Growth
Major companies operating in the cystic fibrosis (CF) therapeutics market report are Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche AG, Vertex Pharmaceuticals Incorporated, Chiesi Farmaceutici SpA, PTC Therapeutics LIMITED, Genentech Inc., Alaxia, AstraZeneca, Beyond Air Inc., Pfizer Inc., Alcresta Therapeutics Inc., Laurent Pharmaceuticals, Nestlé HealthScience, Vivus, Pharmaxis, Genentech, Bayer AG, Eli Lilly and Company, AbbVie Inc., Novartis AG, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc., ProQR Therapeutics N.V., Enterprise Therapeutics Ltd., Corbus Pharmaceuticals Holdings Inc., Eloxx Pharmaceuticals, Translate Bio Inc., Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals Inc., Zambon S.p.A .
Key Industry Players
Major companies operating in the cystic fibrosis (CF) therapeutics market are focused on investing to expand their footprints and strengthen their position in the market. Strategic investment in medical research describes the deliberate and organized distribution of funds, labor, and knowledge into scientific research projects with the goals of expanding our knowledge of medical disorders, creating novel treatments, and enhancing healthcare procedures. In January 2023, the Cystic Fibrosis Foundation (CF Foundation), a US-based non-profit organization that supports a broad range of research initiatives to cure cystic fibrosis, announced a strategic investment of up to $15 million in ReCode Therapeutics, a US-based clinical-stage genetic medicines and biotechnology company that uses superior delivery to power the next wave of messenger ribonucleic acid (mRNA) and gene correction therapeutics. ReCode will use the funds to develop its inhaled mRNA-based therapeutic for people with cystic fibrosis (CF), including those with genotypes that do not respond to approved cystic fibrosis transmembrane conductance regulator (CFTR) modulators.
The cystic fibrosis (cf) therapeutics market report table of contents includes:
1. Executive Summary
2. Cystic Fibrosis (CF) Therapeutics Market Characteristics
3. Cystic Fibrosis (CF) Therapeutics Market Trends And Strategies
4. Cystic Fibrosis (CF) Therapeutics Market – Macro Economic Scenario
5. Global Cystic Fibrosis (CF) Therapeutics Market Size and Growth
.
.
.
31. Global Cystic Fibrosis (CF) Therapeutics Market Competitive Benchmarking
32. Global Cystic Fibrosis (CF) Therapeutics Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Cystic Fibrosis (CF) Therapeutics Market
34. Cystic Fibrosis (CF) Therapeutics Market Future Outlook and Potential Analysis
35. Appendix
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
